Trial · NCT01575834
Adverse events3,056
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 3,056
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | 12-Month Double-blind Period: Placebo | 162 | 3,576 | |
| other | Constipation | Gastrointestinal disorders | 12-Month Double-blind Period: Romosozumab | 138 | 3,581 | |
| other | Constipation | Gastrointestinal disorders | 36-Month Study Period: Placebo/Denosumab | 210 | 3,576 | |
| other | Constipation | Gastrointestinal disorders | 36-Month Study Period: Romosozumab/Denosumab | 189 | 3,581 | |
| other | Diarrhoea | Gastrointestinal disorders | 12-Month Double-blind Period: Placebo | 133 | 3,576 | |
| other | Diarrhoea | Gastrointestinal disorders | 12-Month Double-blind Period: Romosozumab | 111 | 3,581 | |
| other | Diarrhoea | Gastrointestinal disorders | 36-Month Study Period: Placebo/Denosumab | 191 | 3,576 | |
| other | Diarrhoea | Gastrointestinal disorders | 36-Month Study Period: Romosozumab/Denosumab | 182 | 3,581 | |
| other | Influenza | Infections and infestations | 12-Month Double-blind Period: Placebo | 180 | 3,576 | |
| other | Influenza | Infections and infestations | 12-Month Double-blind Period: Romosozumab | 169 | 3,581 | |
| other | Influenza | Infections and infestations | 36-Month Study Period: Placebo/Denosumab | 240 | 3,576 | |
| other | Influenza | Infections and infestations | 36-Month Study Period: Romosozumab/Denosumab | 237 | 3,581 | |
| other | Nasopharyngitis | Infections and infestations | 12-Month Double-blind Period: Placebo | 439 | 3,576 | |
| other | Nasopharyngitis | Infections and infestations | 12-Month Double-blind Period: Romosozumab | 460 | 3,581 | |
| other | Nasopharyngitis | Infections and infestations | 36-Month Study Period: Placebo/Denosumab | 622 | 3,576 | |
| other | Nasopharyngitis | Infections and infestations | 36-Month Study Period: Romosozumab/Denosumab | 651 | 3,581 | |
| other | Upper respiratory tract infection | Infections and infestations | 12-Month Double-blind Period: Placebo | 172 | 3,576 | |
| other | Upper respiratory tract infection | Infections and infestations | 12-Month Double-blind Period: Romosozumab | 161 | 3,581 | |
| other | Upper respiratory tract infection | Infections and infestations | 36-Month Study Period: Placebo/Denosumab | 255 | 3,576 | |
| other | Upper respiratory tract infection | Infections and infestations | 36-Month Study Period: Romosozumab/Denosumab | 236 | 3,581 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01575834/events